statistiche ricercatore

Continente	#
EU - Europa	581
NA - Nord America	514
AS - Asia	242
SA - Sud America	96
Continente sconosciuto - Info sul continente non disponibili	21
AF - Africa	9
OC - Oceania	1
Totale	1.464

Nazione	#
US - Stati Uniti d'America	494
RU - Federazione Russa	323
SG - Singapore	104
BR - Brasile	82
IE - Irlanda	63
SE - Svezia	55
CN - Cina	45
IT - Italia	38
DE - Germania	29
HK - Hong Kong	29
FR - Francia	18
IN - India	15
VN - Vietnam	14
FI - Finlandia	12
GB - Regno Unito	11
CA - Canada	7
PL - Polonia	7
IL - Israele	6
MX - Messico	6
CO - Colombia	5
ES - Italia	4
NL - Olanda	4
SC - Seychelles	4
AE - Emirati Arabi Uniti	3
BD - Bangladesh	3
ID - Indonesia	3
PK - Pakistan	3
TR - Turchia	3
UA - Ucraina	3
VE - Venezuela	3
AR - Argentina	2
AT - Austria	2
CH - Svizzera	2
GE - Georgia	2
IQ - Iraq	2
JM - Giamaica	2
JP - Giappone	2
NP - Nepal	2
PE - Perù	2
RO - Romania	2
RS - Serbia	2
ZA - Sudafrica	2
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CR - Costa Rica	1
CW - ???statistics.table.value.countryCode.CW???	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EC - Ecuador	1
EE - Estonia	1
ET - Etiopia	1
GT - Guatemala	1
KR - Corea	1
LB - Libano	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MA - Marocco	1
MY - Malesia	1
NZ - Nuova Zelanda	1
PH - Filippine	1
PR - Porto Rico	1
PT - Portogallo	1
PY - Paraguay	1
QA - Qatar	1
TT - Trinidad e Tobago	1
Totale	1.444

Nome	#
Sacubitril/Valsartan and implantable cardioverter-defibrillators: evolving therapeutic strategies. A case report	174
An “ordinary” case of COVID-19 pneumonia: when symptoms hide serious complications	165
Cardiac and Vascular Impairment in Patients with Mild Psoriasis: A Longitudinal Study	158
Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure	156
Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases	152
The thromboembolism in COVID-19: the unsolved problem	145
Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation	138
Usefulness of Sacubitril/Valsartan in reduction of atrial fibrillation burden in a patient with ICD delivering inappropriate therapies. A new possibility?	136
Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice	106
Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients	87
Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention	43
RNA-targeted therapeutics in arterial hypertension.	4
Totale	1.464

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	68	0	0	0	0	0	1	2	3	7	31	1	23
2022/2023	176	11	20	5	18	9	17	5	6	75	0	7	3
2023/2024	46	5	7	2	3	3	15	2	1	0	3	3	2
2024/2025	237	2	11	4	16	3	9	12	37	62	15	33	33
2025/2026	777	49	42	48	64	57	139	92	112	102	47	12	13
2026/2027	148	9	21	40	66	12	0	0	0	0	0	0	0
Totale													1.464